# Tigecycline

## Tygacil inj 50mg

##### 臨採

| TAH Drug Code      | [ITYG](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ITYG){:target="_blank"}                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of complicated skin & skin structure infections, complicated intra-abdominal infections & community-acquired pneumonia caused by susceptible microorganisms sensitive to tigecycline.                                                                                                                                                                                                                                                                                                              |
| Dosing             | Adult: a single loading dose of 100 mg IV initially, then 50 mg IV Q12H over 30-60 minutes for 5-14 days.                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Hypersensitivity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Adverse Effects    | Abdominal pain, abscess, asthenia, back pain, fever, headache, infection, pain; HTN, hypotension, phlebitis; constipation, diarrhea, dyspepsia, nausea, vomiting; anemia, leukocytosis, thrombocythemia; increased alkaline phosphatase/amylase/BUN/lactic dehydrogenase/SGOT/SGPT, bilirubinemia, abnormal healing, hyperglycemia, hypokalemia, hypoproteinemia, peripheral edema; dizziness, insomnia; increased cough, dyspnea, pulmonary physical finding; pruritus, rash, sweating; inj site reactions. |
| Pregnancy          | Human Data Suggest Risk in 2nd and 3rd Trimesters                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tigecycline-drug-information){:target="_blank"}                                                                                                                                                                                                                                                                                                                                                                                                                 |

